导读当跨国药企集体穿越专利悬崖风暴,辉瑞用一份“稳中藏锋”的半年报展现了老牌巨头的韧性。2025上半年总营收283.67亿美元,同比微增1%的背后,暗藏关键业务线的剧烈分化:肿瘤板块扛起增长大旗,ADC产品以15亿美元收入成为新引擎,而初级护理业务8%的滑坡则敲响转型警钟。更值得关注的是,手握430亿美金收购Seagen的整合红利尚未完全释放,130亿美元BD弹药已蓄势待发。这家曾被质疑“后新冠...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.